March 7, 2023, SAN DIEGO, CA — In a joint effort to accelerate high-quality therapies to market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, and Stoic Bio, a provider of sustainable technology for cell media manufacturing, have announced plans for a supply agreement with the Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization (CDMO), whose mission is to save lives by accelerating the development and manufacture of advanced therapies. This agreement makes Nucleus Biologics the preferred supplier of cell culture media and other critical biological solutions for CBM; thus, ensuring a steady, consistent supply of this critical material with tighter quality control measures. [Read more…]
Cellular Engineering Technologies Receives Exclusivity to Use John Paul II Medical Research Institute’s Immortalized Human Stem Cells for Commercial Bio-Production Applications
The exclusive right grants Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize next generation bio-production of recombinant proteins, viral vectors for gene therapy and vaccines with a more native human post-translational modification (PTM).
iPSirius Granted Second American Patent for Innovative IPVAC Cancer Vaccine Technology
Paris, March 7 2023 – iPSirius, a leading biotechnology company focused on the development of innovative immunotherapies, announced that it has been granted its second American patent for a novel technology that enables the production of ‘off-the-shelf’ cancer vaccines from induced pluripotent stem cells (iPSCs). [Read more…]
Passive vs Active Loading of Engineered Exosomes
Naïve exosomes can be engineered to load drugs into their lumen using two different technologies: passive drug loading and active drug loading. These “drugs” can include RNAs, proteins, and nucleic acids, as well as other payloads. Today, a growing number of companies are using engineered exosomes for therapeutic purposes and studies by these companies have confirmed that exosomes can effectively serve as carrier vehicles for several types of bioactive molecules. Several exosome therapeutics have also entered into clinical testing. [Read more…]
BELIEVER Meats Breaks Ground on Largest Cultivated Meat Production Facility in The World
-
The company’s first U.S. commercial scale production facility is planned at 200,000 square feet, with possible expansion in the future
-
Once fully operational, the facility’s production capacity will be at least 10,000 metric tons (22 million pounds)
-
The project represents an initial planned investment of $123.35 million in Wilson County, North Carolina
